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0bjecii;yes. This study attempted to clarify the effects of human 
brain (B-type) natriuretic peptide on coronary artery diameter 
and coronary vascular resistance in humans. 
Background. Brain natriuretic peptide induces vasodilation in 
systemic irculation by activating particulate guanylate cyclase of 
the vascular smooth muscle. 
Methods. In 13 patients with normal coronary arteries and left 
ventricular function, brain natriuretic peptide was infused at 
0.5 &kg body weight per min for 4 win into the left main 
coronary artery (six patients, Group X) or into the pulmonary 
artery (seven patients, Group B). Systemic hemodynamic vari- 
ables and coronary sinus blood fiow were measured before and 
after the infusion. The lumen diameter of the left coronary artery 
was quantitatively measured. 
significantly in both groups (both p < 9.01 vs. baseline), and there 
was no difference in the effect behveen the groups. Brain natri- 
uretic peptide decreased coronary vascular resistance in Group A 
(p c 0.01 vs. baseline) but did not affect coronary vascular esistance 
in Group B (p < 0.01 vs. Group A). The lumen diameters of the 
proximal and distal segments of the left coronary artery were 
increased significantly after brain natriuretic peptide in both 
groups. Alter infusion of brain natrluretic peptide, mean plasma 
level of brain natriuretic peptide in the coronary sinus increased 
from 36 to 130,411 pg/ml in Group A and from 64 to 12,329 pglml 
in Group B. 
Results. In both groups, brain natriuretic peptide significantly 
increased heart rate and decreased mean arterial pressure. Rate- 
pressure product remained unchanged in both groups. Brain 
natriutitic peptide decreased systemic vascular resistance index 
Conclusions. Brain natriuretic peptide shows a vasodilator 
effect on the coronary artery system in humans. However, the 
effect does not appear uniformly but is seen preferentially in the 
epicardial coronary artery. The sensitivity of the coronary resis- 
tance vessels to brain natriuretic peptide is low compared with 
that of the resistance vessels of the systemic circulation. 
(J Am Coil Cardiol1995;25:342- 8) 
- 
Brain (B-type) natriuretic peptide was first isolated from a nantly the atria1 natriuretic peptide-A receptor that couples to 
porcine brain (1) and subsequently from the hearts of pigs (2) particulate guanylate cyclase (12). We have shown (5,7,8) that 
and rats (3,4) and has been shown to form a peptide family the plasma levels of brain natriuretic peptide are markedly 
with atria1 (A-type) natriuretic peptide (5). We recently iso- increased in patients with congestive heart failure, as are the 
lated human brain natriuretic peptide from the human atrium, plasma levels of atria1 natriuretic peptide, and surpass atria1 
determined its amino acid sequence (6), established a specific natriuretic peptide levels in severe cases. We have also shown 
radioimmunoassay for human brain natriuretic peptide ($7) (13) that the plasma levels of brain natriuretic peptide are 
and demonstrated that brain natriuretic peptide is secreted increased in patients with acute myocardial infarction. Thus, 
predominantly from the left ventricle (2-5,7,8). Brain natri- brain natriuretic peptide may be involved in the regulation of 
uretic peptide has been shown to stimulate cyclic guanylate 
monophosphate production (9-11) by activating predomi- 
blood pressure and fluid volume, as is atrial natriuretic pep- 
tide. 
From the Division of Cardiology, Kumamoto University School of Medicine, 
Kumamoto, Japan; and *Second Division, Department of Medicine, Kyoio 
University School of Medicine, Kyoto, Japan. Thii study was supported in part by 
Grant-in-Aid for Scientific Research B-03454257 from the Ministry of Education 
and Culture and a grant from the Smoking Research Foundation, Tokyo, Japan. 
Manuscript received June 10, 1994; revised manuscript received August 25, 
1994, accepted September 16, 1994. 
-for Dr. Ken Okumura, Division of Cardiology, 
Kumamoto University School of Medicine, Honjo l-l-l, Kumamoto, 860 Japan. 
Besides its diuretic and natriuretic effects and inhibitory 
effect on the renin-angiotensin-aldosterone system (14-17), 
atria1 natriuretic peptide induces vasorelaxation in a variety of 
organ systems and animal species (l&19). We (20) and other 
investigators (21) have shown that atria1 natriuretic peptide 
infusion improves left ventricular function by reducing both 
preload and afterload in patients with cor,ge;tive heart failure. 
Chu et al. (22) showed that atria1 natriuretic peptide causes 
marked sustained dilation in the proximal coronary artery of 
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humans. I.& et al. (23) recently demonstrated a beneficial 
effect of atria1 natriuretic pcptide on exercise-induced myocar- 
dial ischemia in patients with stable effort angina. We recently 
reported (24) that atria1 natriuretic peptide infusion prevented 
coronary spasm induced by hyperventilation in patients with 
variant angina. 
In contrast to these vigorous investigations on the effects of 
atria1 natriuretic peptide on systemic and coronary vascula- 
tures, only a few studies on the vasodilator effect of brain 
natriuretic peptide have been reported (l&25-27). We recently 
demonstrated (26) that the infusion of human brain natriuretic 
peptide decreases both preload and afterload to the left 
ventricle and improves left ventricular function in patients with 
congestive heart failure. However, the effect of brain natri- 
uretic peptide on the coronary artery system of humans has 
never been reported. 
In the present study, human brain natriuretic peptide was 
infused into the left main coronary artery of patients with 
normal coronary arteriograms and normal left ventricular 
function, and its effects on the coronary artery diameter, 
coronary vascular resistance and systemic hemodynamic vari- 
ables were examined. Furthermore, the same dose of the 
peptide was infused into the puhr iary artery in another 
group of the patients to clarify whether brain natriuretic 
peptide administered into systemic circulation shows its effects 
on the coronary vasculature as it does on the peripheral 
resistance vessels of systemic circulation. 
Methods 
Study patients. This study included 13 (4 men, 9 women; 
mean age 54 years, range 34 to 65) patients who underwent 
coronary angiographic examination for an atypical chest pain 
syndrome (12 patients) or an electrocardiographic (ECG) 
abnormality (T wave inversion in the pr-,cordial leads [l 
patient]). These patients were found to have no angiographic 
stenosis ~25% of the lumen diameter in any coronary artery 
segments. None of the patients had typical angina1 pain at rest 
or on exertion. Maximal exercise stress test results according to 
the Bruce standard protocol were negative in all patients. 
Hyperventilation test results for provoking coronary spasm 
were negative for myocardial ischemia in ali patients. Intra- 
coronary injection of acetylcholine was performed in an at- 
tempt to provoke coronary spasm in all patients before the 
study (28,29). Neither chest pain nor ischemic ST segment 
changes appeared, and coronary arteriography showed no 
evidence of coronary spasm in any of the patients. 
None of the patients had diabetes mellitus. Two patients 
had hypertension, with systolic blood pressure >160 but 
~180 mm Hg and diastolic pressure ~100 mm Hg at admis- 
sion. No patient had a serum cholesterol level >250 mgldl. 
Four patients had a history of smoking. Echocardiograp!ty 
revealed normal left ventricular wall motion and normal wall 
thickness in all patients. Right- and ieft-sided cardiac catheter- 
izations showed normal hemodynamic data in all patients, and 
mean (?SD) left ventricular ejection fraction was 7g.5 rt 6.8%. 
None of the patients had congestive heart failure or allergy. All 
drugs were withdrawn at least 3 days before the study. Written 
informed consent was obtained from all patients before the 
study. The study protocol was in agreement with the guideiines 
approved by the ethics committee at our institution, 
Synthetic human brain natriuretic peptide. Human brain 
natriuretic peptide was purchased from Peptide Institute (Mi- 
noh, Japan). Its homogeneity was confirmed by reverse-phase, 
high performance liquid chromatography and amino acid 
analysis. The human brain natriuretic peptide was dissolved in 
saline solution with 10% lactose and sterilized by passage 
through a 0.22-km Millipore filter. The chemical nature and 
content of brain natriuretic peptide in vials were verified by 
high performance liquid chromatography and radioimmuno- 
assay. 
Cardisc catheterization and aagiomphic study. The study 
was performed in the morning while the patients we:e in the 
fasting state. A 7F thermodilution coronary blood flow cathe- 
ter (CC!&7U-90B, Webster) was positioned in the coronary 
sinus by way of the antecubital vein. The catheter position was 
determined by injection of a small volume of contrast medium 
(Hexabrix 320), and a stable catheter position was confirmed 
by fluoroscopy during the procedure. Coronary arteriagraphy 
was performed with the Sones technique. The left coronary 
artery was filmed in the right anterior oblique projection and 
the right coronary artery in the left anterior oblique projection. 
Relations among the focal spot, the patient and the height of 
the image tube were kept constant throughout the study. Three 
ECG leads (1, aVF and V,) and arterial pressure were 
continuously monitored on an oscilloscope during the study. 
Coronary sinus blood flow was determined by the injection 
of nonheparinized normal saline solution through the ther- 
modilution catheter with a constant-infusion pump at a rate of 
36 ml/min and calculated with the use of a Therm0 Flow RF 
(Good Man) (30). The flow curve was recorded on oscillo- 
graphic paper along with three ECG leads and arterial pres- 
sure. 
Study protocol. After the baseline measurements of coro- 
nary sinus blood flow, pulmonary artery, right atria1 and aortic 
pressures and cardiac output (with a thermodilution tech- 
nique), and after a control arteriogram of the left coronary 
artery, brain natriuretic peptide solution was infused at 
0.5 pgkg body weight per min for 4 min into the left coronary 
artery (six patients, Group A) or into the pulmonary artery 
(seven patients, Group B). The infusion rate was 2 ml/min. 
Coronary sinus blood flow was measured just before termina- 
tion of the infusion of brain natriuretic peptide, and the blood 
samples were obtained from the coronary sinus and femoral 
vein. The left coronary arteriogram was taken just after 
termination of brain natriuretic peptide infusion, and pressures 
and cardiac output were measured. Measurements of coronary 
sinus blood flow and hemodynamic variables, left coronary 
angiography and blood sampling from the femoral vein were 
repeated at 5, JO and 20 min after termination of the infusion 
of brain natriuretic peptide. Isosorbide dinitrate (1 mg) was 
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Table 1. Changes in Systemic Hemodynamic Variables After Brain Natriuretic Peptide Infusion Into the Coronary and Pulmonary Arteries 
Time After BNP I&sum (min) - 
Baseline 0 S 10 20 
Infusion Into Coronary Artery (Group A) 
Heart rate (beats/&) 73% 11 84 5 13* 88 i 17* 88 f 14% $4 t I!* 
Mean arterial (mm Hg) pressure 105 ? 1 95 j: 10* 94 2 8f 96 i 9* 99 t Y 
Rate-pressure product (mm Hgbeatsimin) 10,152 2 1,58? 10,448 2 1,699 10,738 + 2,023 10,666 It 1,850 10,427 f 1,274 
Mean pulmonary artery (mm Hg) pressure 14 + 3 13 zf 3 13 + 4 13 2 2 12t2t 
Cardiac index (litersimin m2) per 3.2 -c 0.5 3.9 I 0.7’ 3.9 5 0.8” 3.7 i Lo* 3,s t 0.8 
Systemic vasctilar resistance index (dynesscm-‘.m*) 2,587 2 353 1,865 f 332* 1,866 + 335* 2,037 It 552* 2,244 2 57% 
Infusion Into Pulmonary Artery (Group E) 
Heart rate (beats/m@ 
Mean arterial (mm Hg) pressure 
Rate-pressure product (mm Hgbeats!min) 
Mean pulmonary artery (mm Hg) pressure 
Cardiac index (liters/min m’) per 
Svstemic vascular resistance index (dvnesscm-‘.m2) 
69 2 12 74 -’ 14t 80 i 17* 82 2. 15” 79 + 16t 
101 c 12 96 f 12t 88 2 8’ 88 + 11% 89 2 11* 
10,255 rt 1,560 10,137 c 1,739 10,074 + 2,146 9,967 i 1,152 9,846 t 2,314 
13 i: 4 10 z 4’ 10 2 4’ 10 c s 10 2 4* 
3.0 L 0.5 3.5 f OS4 3.5 2 0.4’ 3.3 -c 0.4t 3.3 i 0.4t 
2,587 ? 329 2,126 r 332* 1,934 + 95’ 1,993 1274% 2.030 2 272* 
*p < 0.01, tp i 0.05 vzrscs baseline. Data are mean value 5 SD. BNP = brain (B-type) natriuretic peptide. 
finally injected into the left coronary artery, and the *nmc:?; 
arteriogran was taken from multiple projections. 
Quantitative coronary angiography. Measurement of the 
lumen diameter of the left coronary artery was performed 
quanfiratively with the use of a computer-assisted coronary 
angiography analysis system. End-diastolic tine films were 
videodigitized and stored in the cardiac image analysis system 
(Cardio 500, Kontron Instruments). Automated contour de- 
tection was performed by a geometric edge differentiation 
technique similar to the method described by Reiber et al. 
(31), and the technique was validated in our previous study 
(32). Analysis of intraobserver and interobserver variability for 
the measurement of the coronary artery diameter with this 
system showed high reproducibility (r = 0.99, SEE 0.05 mm, 
p < 0.001 and r = 0.99, SEE 0.04 mm, p < 0.001, respectively). 
The lumen diameters were measured at the proximal and 
distal segments of the left anterior descending and circumflex 
coronary arteries (the length of each segment was -1 cm). The 
measurement was performed for the arteriogram at baseline, 
those at 0,5, 10 and 20 min after brain natriuretic peptide and 
that after isosorbide dinitrate. 
Measurement of plasma concentration of brain natriutetic 
peptide. Plasma concentration of brain natriuretic peptide was 
measured with a specific radioimmunoassay by using monoclo- 
nal antibody that recognized the ring structure of human brain 
natriuretic peptide, and the minimal detectable quantity of 
human brain natriuretic peptide was 1 pg/tube as previously 
reported (5,7). The cross-reactivity with alpha-human atria1 
natriuretic peptide was <0.005% on a molar basis. The intra- 
assay and interassay coefficients of variation were 8.4% and 
6.4%, respectively. 
Calculation and data analysis. Coronary vascular resis- 
tance (mm Hgmin liter) was calculated as (Mean aortic blood 
pressure - Right atria! pressure) X lOOO/Coronary sinus blood 
flow; systemic vascular resistance index (tiyness~cm-5*m’) as 
(Mean arterial pressure - Right atria1 prewnre) X SO/Cardiac 
index; and rate-pressure product (mm Hgbeats/min) as Heart 
rate X Systolic blood pressure. 
All data are shown as mean value 2: 1 SD. The lurien 
diameters of the left anterior descending and circumflex 
coronary arteries were averaged for each of the proximal and 
distal segments. When serial changes in the systemic and 
coronary hemodynamic variables, the lumen diameters of the 
proximal and distal segments of the left coronary artery and 
the plasma levels of brain natriuretic peptide (expressed as 
logarithms) in the femoral vein and coronary sinus after 
infusion of brain oatriuretic peptide were compared within a 
group, one-way analysis of variance for repeated measures 
followed by the Fisher protected least-significant-difference 
multiple-comparison test was used. Percent changes in sys- 
temic and coronary hemodynamic variables and lumen diam- 
eters of the left coronary artery from the baseline values after 
brain natriuretic peptide were compared between groups using 
two-way anzlysis of variance for repeated measures. A p value 
CO.05 was considered statistically significant. 
Results 
Elects on systemic hemodynamic variables. In both 
groups, the infusion of brain natriuretic peptide resulted in a 
significant increase in heart rate, a significant decrease ir mean 
arterial pressure, a significant increase in cardiac index and a 
significant decrease in systemic vascular resistance index (Ta- 
ble 1). These effects of brain natriuretic peptide continued for 
>lO min in both groups. Rate-pressure product remained 
uschanged after brain natriuretic peptide in both groups. 
Mean pulmonary artery pressure decreased significantly at 
20 min after brain natriuretic peptide in Group A, whereas it 
decreased immediately after the infusion in Group B. 
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Table 2. Changes in Coronary Hemodynamic Variables After Brain Natriuretic Peptide Infusion Into the Coronary and Pulmonary Arteries 
- 
Time Afwr BNP Infusion (min) 
Baseline 0 5 10 20 
-- 
Infusion Into Coronary Artery (Group A) 
--“. 
Coronary sinus blood flow (mlimin) 90 i 26 104 2 36 112 2 36* 105 2 44 99 2 42 
Coronary vascular resistance (mm Hgmiwliter) 1,268 i 40.5 991 -c 370t 916 I?: 311* 1,052 i 450t 1,166 + 5bO 
Infusion Into Pulmonav Artery (Group B) 
Coronary sinus blood flow (mUmin) 111 r 46 98 It 25t 88 5 26’ 91 2 29” 87 2 30’ 
Coronaty vascular resistance (mm Hgminkter) 1,087 + 440 1,070 -c 358 1,113 ? 346 1,133 ?I 435 1,153 ? 333 
*p < 0.01, tp <: 0.05 versus Ltse!inc. Data presented are mean value f SD. BNP = brain (B-type) natriuretic peptide. 
Ekets on coronary hemodynamic variables. In Group A, 
coronary sinus blood flow increased significantly at 5 min after 
the infusion of brain natriuretic peptide, and coronary vascular 
resistance decreased significantly immediateiy after the infu- 
sion (Table 2). The effect on the latter continued for >lO min 
after the infusion. In contrast, coronary sinus blood flow 
decreased significantly, and coronary vascular resistance re- 
mained unchanged after brain natriuretic peptide in Group 9. 
Effects on coronary artery diameters. The baseline lumen 
diameter of the proximal segment of the left coronary artery 
was 3.1 2 0.4 mm in Group A and 3.1 f 0.6 mm in Group R. 
In Group A, the diameter increased to 3.4 t 0.4 mm imme- 
diately after the infusion of brain natriuretic peptide (p < 
0.001) and increased further to 3.6 it 0.4 mm at 10 min after 
the infusion (Fig. 1). In Group B, the diameter increased to 
Figure 1. Time course of the effects of brain natriuretic peptide (BNP) 
infused into the left main coronary artery (Group A) or the pulmonary 
artery (Group B) and intracoronary isosorbide dinitrate (ISDN) on the 
lumen diameter of the proximal segment of the left coronary artery. 




Baseline 0 5 10 20 ISDN 
Time After BNP (minute) 
3.5 + 0.6 mm at 5 min after brain natriuretic peptide (p < 
0.001). After isosorbide dinitrate, the diameter increased fur- 
ther in Group B but not in Group A. A similar observation was 
made in the distal segment. The baseline diameter was 1.4 2 
0.4 mm in Group A and 1.4 2 0.2 mm in Group B. In Group 
A, the diameter increased to 1.6 -C 0.4 mm immediately after 
brain natriuretic peptide (p < O.OOl), whereas in Group B, it 
increased to 1.7 2 0.3 mm at 5 min after brain natriuretic 
peptide (p < 0.001). 
Changes in plasma concentration. The infusion of brain 
natriuretic peptide resulted in an immediate and marked 
increase in the plasma concentrations in the femoral vein and 
coronary sinus in both groups (Table 3). The concentration in 
the coronary sinus in Group A was - 10 times higher t! an that 
in Group B. 
Comparison of the effects between Groups A and B. None 
of the baseline variables differed between the two groups. 
None of the percent changes in the heart rate, mean arterial 
pressure, cardiac index and lumen diameters of the proximal 
and distal segments of the left coronary artery from baseline 
after the infusion of brain natriuretic peptide was different 
between the groups. There was a significant difference in the 
change in the mean pulmonary artery pressure between the 
two groups (p = 0.0167). 
There was a significant difference in the change in coronary 
sinus blood flow after brain natriuretic peptide between the 
two groups (p = 0.0023). Figure 2 shows the time course of the 
percent changes from the baseline in systemic vascular resis- 
tance index and coronary vascular resistance after brain natri- 
uretic peptide for both groups. There was no statistical differ- 
ence in the change in systemic vascular resistance index 
between the groups. However, a significant difference was 
noted in the change in coronary vascular resistance behveen 
the two groups (p = 0.0046). 
Discussion 
Brain natriuretic peptide, first isolated from a porcine brain 
(1) and subsequently from the hearts of pigs (2) and rats (3,4), 
is secreted predominantly from the ventricles in humans 
(2-5,7,8) and forms a natriuretic peptide family with atria1 
natriuretic peptide (5). We and the other investigators (5,7,8) 
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Table 3. Charges in Plasma Brain Natriuntic Peptide Concentration After Infusion Into Coronary tiar! Prltmonary Arteries - -~_I-.~ 
Time After BNP Infusion (min) 
.-I-_ 
Sampling Site Baseline 0 5 10 
.-- 
Infusion Into Coronary Artery (Croup A) 
_-- - 
Femoral vein (pg/ml) 14 - 11 6,704 f 1,886* 3,503 k 828* 2,209 i 1,035’ 
Coronary sinus (pgiml) 36 c 43 130,411 k 52,084* 
20 
919 i 244 
Infusion Into Pulmonary Artery (Group B) 
Femoral vein (pgiml) 25 c 15 10,201 f 2,838’ 4,501 2 1,437* 2,389 2 6781 1,016 2 344 
Coronary sinus (pg/ml) 64 2 45 12,329 + 2,731* 
*p < 0.01, tp < 0.05 versus baseline. Data presented are mean value 2 SD. BNP = brain (B-type) natriuretic peptide. 
have shown that the plasma levels cf brain natriuretic peptide 
are markedly increased in patients with congestive heart 
failure, as are the plasma levels of atria1 natriuretic peptide. 
We have also shown (13) that the plasma levels of brain 
natriuretic peptide are increased in patients with acute myo- 
cardial infarction. Thus, brain natriuretic peptide seems to be 
involved in the regulation of blood pressure and fluid volume, 
as is atria1 natriuretic peptide (14-17). 
Brain natriuretic peptide stimulates cyclic guanylate mono- 
phosphate production (9-ll), predominantly by activating the 
atrial natriuretic peptide-A receptor that couples to particulate 
guanylate cyclase (12) and thereby induces vasorelaxation. The 
biologic action of brain natriuretic peptide was shown to be 
species specific, unlike atria1 natriuretic peptide: Human brain 
natriuretic peptide shows much less vasodiiative effect on the 
Figure 2. Time course of the percent changes from baseline in 
systemic vascular resistance index (SVRI) and coronary vascular 
resistance (CVR) after brain natriuretic peptide (BNP) infusion into 
the left main coronary artery (Group A, closed circles) or the 
pulmonary artery (Group B, open circles). There was no difference in 
the change in systemic va?cucular resktance index between the two groups, 
whereas a significant difference was noted in the change in coronary 
vascular resistance (p = 0.0046 by two-way analysis of variance). 
-40’ 1 f 
Baseline 0 5 10 20 
Time After BNP (minute) 
rat thoracic aorta than rat brain natriuretic peptide and rat 
atrial natriuretic peptide while showing more potent vasodila- 
tion in the porcine coronary artery than the other peptides 
(25). It was also reported (11) that human brain natriuretic 
peptide showed lower cyclic guanylate monophosphate accu- 
mulation in the rat vascular smooth muscle and less vasorelax- 
ant activity in the rat aorta than rat and porcine brain 
natriuretic peptides despite its high binding affinity to the rat 
vascular smooth muscle. We examined the effects of human 
brain natriuretic peptide on systemic hemodynamic variables, 
renal function and plasma hormone levels in patients with 
congestive heart failure and in control subjects and demon- 
strated that brain natriuretic peptide significantly decreased 
systemic vascular resistance and significantly increased both 
diuresis and natriuresis (26). Human brain natriuretic peptide 
may have similar vasodilative effects on the coronary artery 
system of humans, but such data have not been reported 
pi-eviously. 
Vasodilator effect of brain natriuretic peptide on the epi- 
cardial coronary artery. The results of this study showed that 
the lumen diameters of both proximal and distal segments of 
the epicardial coronary artery increased significantly after the 
infusion of brain natriuretic peptide into the left coronary and 
pulmonary arteries. Because the rate-pressure product, a 
marker of myocardial oxygen consumption rate, remained 
unchanged after brain natriuretic peptide in both groups, and, 
furthermore, coronary blood flow rather decreased after brain 
natriuretic peptide in Group B, the epicardial coronary artery 
dilation seen after brain natriuretic peptide was a result of its 
primary vasodilator effect, presumably through the production 
of cyclic guanylate monophosphate (9-12). 
As indicated by the time course of the effect of brain 
natriuretic peptide (Fig. l), the lumen diameter change was 
not maximal at the time immediately after the infusion (i.e., at 
the time when the plasma concentration of brain natriuretic 
peptide was the highest), and the diameter further increased 
with time after cessation of the infusion. In Group A, the 
maximal vasodilation was obtained at 10 to 20 min after the 
infusion because isosorbide dinitrate showed no further dilator 
effect. Thus, the vasodilator Sect of brain natriuretic peptide 
on the ipicardiar coronary arteq not only was sustained for at 
least 20 min but enhanced with time after the infusion. After 
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the infusion of atria1 or brain satriuretic pcptide, the plasma 
levei of cyclic guanylate monophosphate was shown to increase 
and reach its peak -5 min later than the peak of the plasma 
level of atria1 or brain natriuretic peptide (22,24,26). Further- 
more, it was sustained at higher levels even after the plasma 
level of atria1 or brain natriuretic peptide returned to the 
baseline value. Such delayed and sustained elevation of the 
cyclic guanylate monophc;phate level after brain natriuretic 
peptide may account for the time course of the >tIect of brain 
natriuretic peptide. 
It has been shown that atriai natriuretic peptide induces 
vasorelaxation iu a variety of organ systems and animal species 
(l&19). Chu et al. (22) administered atria1 natriuretic peptide 
in humans as a So&s (2.5 &kg) and demonstrated that atria1 
natriuretic peptide indul,d marked, sustained dilation in the 
proximal coronary artery and brief minor change in coronary 
blood flow. Lai et al. (23) recently demonstrated beneficial 
effects of atria1 natriuretic peptide on exercise-induced myo- 
cardial ischemia in patients with stable effort angina through 
improvement of myocardiaf perfusion to the ischemic region. 
We recently reported (24) lnat the infusion of atria! natriuretic 
peptide prevented coronary spasm induced by hyperventilation 
in patients with variant angina. Thus, atrial natriuretic peptide 
seems to be beneficial for treatment of myocardial ischemia. 
However, the role of brain natriuretic peptide in the treatment 
of myocardial ischemia has been unclear. We recently showed 
(33) that intravenous infusion cf brain natriuretic peptide at 
0.05 pg/kg per min for 20 min effectively prevented coronary 
spasm induced by hyperventilation in patients with variant 
angina. This can be explained by the primary vasodilator effect 
of brain natriuretic peptide on the epicardial coronary artery. 
Effect of brain natriuretic peptide on the coronary resis- 
tance vessels. When brain natriuretic peptide was inftised into 
the left coronary artery, it increased coronary sinus blood flow 
and decreased coronary vascular resistance as well as systemic 
vascular resistance. This indicates that brain natriuretic Fep- 
tide shows a vasodilator eiIect on both corouary and sy.;;emic 
resistance vessels. In contrast. when brain natriuretic peptide 
was administered in the pulmonary artery, it decreased coro- 
nary sinus blood flow and did not affect coronary vascular 
resistance while decreasing systemic vascular resistance. The 
analysis of the plasma levels of brain natriuretic peptide 
revealed that when the peptide was infused into the coromty 
artery (Group A), its plasma level in the coronary sinus was 10 
to 20 times higher than that in the femoral vein, whereas when 
the peptide was infused into the pulmonary artery (Group B), 
its plasma level in the coronary sinus was almost equal to that 
in the femoral vein. Because the change in mean arterial 
pressure (i.e., coronary perfusion pressure) after the infusion 
of brain natiuretic peptide was not different between the two 
groups, brain nattiuretic peptide is likely to show its vasodila- 
tor effect on the coronary resistance vessels only when the 
plasma level in coronary circulation is extremely increased. 
Thus, the sensitivity of the coronary resistance vessels to the 
vasodilator effect of brain natriuretic peptide is low compared 
with that ol the peripheral resistance vessels of systemic 
circulation and also that of the epicardial coronarqi artery. 
The mechanism for the disparity of the sensitivity to the 
vasodilator effect of brain natritiretic peptide between the 
coronary conduit artery and resistance vessels and between 
Loronary and sysrzmic resistance vessels was not clarified in 
this study. The distribution of the atria1 natriuretic peptide-A 
receptors in the coronary resistance vessels may be different 
from that in the other vascular systems. It has been reported 
(22) that atria1 natriuretic peptide also shows its effect prefer- 
entially on the proximal coronary artery rather than the distal, 
resistance vessels in humans. The role of particulate guanylate 
cyclase-mediated vasodilation is thus suggested to be of less 
importance in the coronary resistance vessels than in the 
epicardia1 conduit artery and systemic peripheral vessels. It 
should be recalled that nitroglycerin, a soluble guanylate 
cyclase activator (34), also exhibits a smaller vasodilator effect 
on the coronary resistance vessels while markedly dilating the 
epicardial conduit coronary artery (35). Brain natriuretic pep- 
tide, when infused into the systemic circulation, seems to show 
a vasodilator effect similar to nitroglycerin. 
Finally, it should be emphasized that the plasma level of 
brain natriuretic peptide v:as markedly increased after the 
infusion of brain natriuretic peptide in both groups (-SOO-fold 
increase in the femoral vein just after the infusion). Thus, the 
effects of brain natriuretic peptide shown in the present study 
were not those at its physiologic level but those of the 
pharmacologic dose. Plasma levels of brain natriuretic peptide 
are markedly increased in patients with congestive heart failure 
(5,7,8). In patients with severe left ventricular dysfunction, it is 
not unusual to see a plasma level of brain natriuretic peptide 
~1,000 pg/ml in the peripheral vein (8). Further studies are 
necessary to clarify whether highly increased brain natriuretic 
peptide levels in patients with congestive heart failure act as a 
physiologic vasodilator in the coronary vasculature. 
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